|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Pittsburgh |
|---|---|
| Collaborators: |
American Association for Geriatric Psychiatry Janssen Pharmaceuticals |
| Information provided by: | University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT00222807 |
Purpose
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.
Regardless the treatment status, we collect the same neuroendocrine-immune data on the participants after 2 months.
| Condition |
|---|
|
Schizophrenia Schizoaffective Disorder Delusional Disorder |
| Study Type: | Observational |
| Study Design: | Case Control, Prospective |
| Official Title: | Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus |
blood samples are collected, stored at minus 70 degree C and analyzed in batches.
| Estimated Enrollment: | 150 |
| Study Start Date: | August 2003 |
| Estimated Study Completion Date: | December 2009 |
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.
Regardless the treatment status, we collect the same neuroendocrine-immune on the participants (patients and controls) after 2 months. Thus, our study does not control treatment. Patients take treatment in consultation with their physician. Some of them even decide not to take any medications. At the 2nd visit, we do ask them about the the medications they are taking if any.
Eligibility| Ages Eligible for Study: | 14 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Patients with psychosis
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Ripu D Jindal, MD | 412 512 9516 | jindalr@upmc.edu |
| United States, Pennsylvania | |
| University of Pittsburgh | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Contact: Richard S Guido, MD 412-383-1480 guidrs@upmc.edu | |
| Principal Investigator: Ripu D Jindal, MD | |
| Sub-Investigator: Matcheri S Keshavan, MD | |
| Sub-Investigator: Kevin Eklund, BSN | |
| Sub-Investigator: Govner Thorp, BS | |
| Principal Investigator: | Ripu D Jindal, MD | University of Pittsburgh |
More Information
| Responsible Party: | University of Pittsburgh ( Ripu Jindal, MD Clinical Assistant Professor ) |
| Study ID Numbers: | 0306110 |
| Study First Received: | September 13, 2005 |
| Last Updated: | November 5, 2008 |
| ClinicalTrials.gov Identifier: | NCT00222807 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
schizophrenia, psychosis, type 2 diabetes mellitus |
|
Disease Metabolic Diseases Tranquilizing Agents Physiological Effects of Drugs Psychotropic Drugs Diabetes Mellitus Central Nervous System Depressants Endocrine System Diseases Antipsychotic Agents Pharmacologic Actions |
Schizophrenia Schizophrenia, Paranoid Pathologic Processes Mental Disorders Therapeutic Uses Psychotic Disorders Glucose Metabolism Disorders Central Nervous System Agents Schizophrenia and Disorders with Psychotic Features |
